| hightlight |
Hightlights {#622
-id: 112
-titre: "Mortalité toutes causes et traitement par statines chez les patients atteints d’insuffisance cardiaque à fraction d’éjection préservée (ICFEP) : méta-analyse"
-titreEn: "Systematic review and meta-analysis of the association between all-cause mortality and statin therapy in patients with preserved ejection fraction heart failure (HFpEF)"
-description: """
<p><span style="font-size:12pt"><span style="background-color:white"><span style="font-family:"Times New Roman",serif"><strong><span style="color:#212121">Méthodologie : </span></strong></span></span></span></p>\r\n
\r\n
<p><span style="font-size:12pt"><span style="background-color:white"><span style="font-family:"Times New Roman",serif"><strong><span style="color:#212121">-</span></strong><span style="color:#212121">une revue systématique et une méta-analyse explorant une association entre l’ICFEP et l’utilisation de statines sur la mortalité toutes causes confondues et la réhospitalisation cardiovasculaire.</span></span></span></span></p>\r\n
\r\n
<p><span style="font-size:12pt"><span style="background-color:white"><span style="font-family:"Times New Roman",serif"><span style="color:#212121"> Des recherches ont été effectuées dans MEDLINE via Ovid, Cochrane Library pour les essais cliniques dans CENTRAL et Embase via Ovid pour les articles publiés entre le 1er janvier 2000 et le 2 juillet 2021.</span></span></span></span></p>\r\n
\r\n
<p><span style="font-size:12pt"><span style="background-color:white"><span style="font-family:"Times New Roman",serif"><strong><span style="color:#212121">Résultats :</span></strong></span></span></span></p>\r\n
\r\n
<p><span style="font-size:12pt"><span style="background-color:white"><span style="font-family:"Times New Roman",serif"><strong> </strong><span style="color:#212121">Au total, 19 études ont été incluses dans la revue. L’analyse suggère une réduction du risque de 27% pour les participants sous statines par rapport aux participants sans statines (HR 0,73, IC à 95%: 0,68-0,79) en ce qui concerne la mortalité toutes causes confondues. </span></span></span></span></p>\r\n
\r\n
<p><span style="font-size:12pt"><span style="background-color:white"><span style="font-family:"Times New Roman",serif"><span style="color:#212121">Il existe un faible niveau d’hétérogénéité (I<sup>2</sup> = 38 %) associé à ce résultat qui a été pris en compte par l’utilisation d’un modèle à effets aléatoires, mais étant donné que les études incluses sont observationnelles, la qualité des preuves est jugée faible. Les informations sur la réhospitalisation étaient insuffisantes pour déterminer l’impact de l’utilisation de statines sur les réhospitalisassions.</span></span></span></span></p>\r\n
\r\n
<p><span style="font-size:11pt"><span style="background-color:#fafafa"><span style="font-family:Calibri,sans-serif"><strong><span style="font-size:12.0pt"><span style="color:black">Quel message clé ?</span></span></strong></span></span></span></p>\r\n
\r\n
<p><span style="font-size:12pt"><span style="background-color:white"><span style="font-family:"Times New Roman",serif"><span style="color:#505050">Il y a un manque d’options de prise en charge fondées sur des données probantes pour les patients atteints d’insuffisance cardiaque à fraction d’éjection préservée</span></span></span></span></p>\r\n
\r\n
<p><span style="font-size:12pt"><span style="background-color:white"><span style="font-family:"Times New Roman",serif"><span style="color:#505050">Cette revue a montré une réduction du risque chez les patients sous statines pour la mortalité toutes causes confondues.</span></span></span></span></p>\r\n
\r\n
<p><span style="font-size:12pt"><span style="background-color:white"><span style="font-family:"Times New Roman",serif"><span style="color:#505050">Considérant que les statines sont largement disponibles, les résultats montrent des résultats prometteurs.</span></span></span></span></p>\r\n
\r\n
<p><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><strong><span style="font-size:12.0pt"><span style="color:#333333">Références</span></span></strong></span></span></p>\r\n
\r\n
<p><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="background-color:white"><span style="font-family:"Times New Roman",serif"><span style="color:#212121">Kaur G, Jones M, Howes L, Hattingh HL. Systematic review and meta-analysis of the association between all-cause mortality and statin therapy in patients with preserved ejection fraction heart failure (HFpEF). Int J Cardiol. 2023 Feb 1;372:63-70. doi: 10.1016/j.ijcard.2022.12.006. Epub 2022 Dec 7. PMID: 36496040.</span></span></span></span></span></span></p>
"""
-descriptionEn: """
<p><span style="font-size:12pt"><span style="background-color:white"><span style="font-family:"Times New Roman",serif"><strong><span style="color:#212121">Methods: </span></strong></span></span></span></p>\r\n
\r\n
<p><span style="font-size:12pt"><span style="background-color:white"><span style="font-family:"Times New Roman",serif"><span style="color:#212121">- a systematic review and meta-analysis exploring an association between HFpEF and statin use on all-cause mortality and cardiovascular rehospitalisation. Searches were conducted in MEDLINE via Ovid, The Cochrane Library for clinical trials in CENTRAL and Embase via Ovid for articles published between 1 January 2000 and 2 July 2021. </span></span></span></span></p>\r\n
\r\n
<p><span style="font-size:12pt"><span style="background-color:white"><span style="font-family:"Times New Roman",serif"><strong><span style="color:#212121">Results: </span></strong><span style="color:#212121">A total of 19 studies were included in the review. The analysis suggests a risk reduction of 27% for the statin exposed participants compared to the statin non-exposed participants (HR 0.73, 95% CI: 0.68-0.79) with regard to all-cause mortality. There is a low level of heterogeneity (I<sup>2</sup> = 38%) associated with this result that has been accounted for by using a random effects model, however given the included studies are observational, the quality of the evidence is rated as low. Information on rehospitalisation was insufficient for determining the impact of statin use on rehospitalisations.</span></span></span></span></p>\r\n
\r\n
<p><span style="font-size:11pt"><span style="background-color:#fafafa"><span style="font-family:Calibri,sans-serif"><strong><span style="font-size:12.0pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">What’s the highlight?</span></span></span></strong></span></span></span></p>\r\n
\r\n
<p><span style="font-size:12pt"><span style="background-color:white"><span style="font-family:"Times New Roman",serif"><span style="color:#505050">There is a lack of evidence-based management options for patients with preserved ejection fraction heart failure</span></span></span></span></p>\r\n
\r\n
<p><span style="font-size:12pt"><span style="background-color:white"><span style="font-family:"Times New Roman",serif"><span style="color:#505050">This review showed a risk reduction in patients on statins for all-cause mortality.</span></span></span></span></p>\r\n
\r\n
<p><span style="font-size:12pt"><span style="background-color:white"><span style="font-family:"Times New Roman",serif"><span style="color:#505050">Considering that statins are widely available, the results show promising outcomes.</span></span></span></span></p>\r\n
\r\n
<p><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><strong><span style="font-size:12.0pt"><span style="font-family:"Times New Roman",serif"><span style="color:#333333">References</span></span></span></strong> </span></span></p>\r\n
\r\n
<p><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><a name="_Hlk127130467"><span style="font-size:12.0pt"><span style="background-color:white"><span style="font-family:"Times New Roman",serif"><span style="color:#212121">Kaur G, Jones M, Howes L, Hattingh HL. Systematic review and meta-analysis of the association between all-cause mortality and statin therapy in patients with preserved ejection fraction heart failure (HFpEF). Int J Cardiol. 2023 Feb 1;372:63-70. doi: 10.1016/j.ijcard.2022.12.006. Epub 2022 Dec 7. PMID: 36496040.</span></span></span></span></a></span></span></p>
"""
-descriptionSansEditeur: null
-titrePhoto: "Mortalité toutes causes et traitement par statines chez les patients atteints d’insuffisance cardiaque à fraction d’éjection préservée (ICFEP) : méta-analyse"
-categorieHightlights: CategorieHightlights {#576 …}
-affiche: "00cdae75dcf69614f41f9c0a1d91ced5.jpeg"
-file: null
#photoHightlights: PersistentCollection {#583 …}
} |